Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30595912 | 0.95 | ALOX15 (0.55) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL28994232 | 0.90 | BTK (0.62) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL27826350 | 0.89 | ALDH1A1 (0.52) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL17392022 | 0.87 | DEGS1 (0.62) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL3476295 | 0.86 | TSHR (0.67) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL15904287 | 0.86 | TSHR (0.62) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL30362452 | 0.86 | TSHR (0.62) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL16594252 | 0.86 | GRM5 (0.53) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL30050714 | 0.86 | GRM5 (0.53) | ALOX15TSHRCASP1NPSR1HSD17B10 | |
| SCHEMBL16604279 | 0.86 | SORT1 (0.60) | ALOX15TSHRCASP1NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105922-A | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4006035-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NEUPHARMA INC (US) | 2023-11-22 | — | — | EP | claimed |
| CN-110291086-B | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-08-11 | — | — | CN | claimed |
| EP-3601264-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Liao, Xibin (US) | 2020-02-05 | — | — | EP | claimed |
| EP-3555090-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-23 | — | — | EP | claimed |
| WO-2018175512-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUZHOU BAIJIBUGONG PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2018-09-27 | — | — | WO | claimed |
| WO-2018112136-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | claimed |
| EP-3240542-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109215-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | claimed |
| EP-2734523-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | claimed |
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | claimed |
| EP-2552905-A1 | B-RAF KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-02-06 | — | — | EP | claimed |
| WO-2013010869-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | claimed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | claimed |
| US-12291534-B2 | Aminonorbornane derivative and manufacture method therefor and use thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-06 | — | — | US | disclosed |
| EP-3240542-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-11974999-B2 | Bruton's tyrosine kinase inhibitors | Liao, Xibin (US) | 2024-05-07 | — | — | US | disclosed |
| WO-2013010869-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291534-B2 | Aminonorbornane derivative and manufacture method therefor and use thereof | BTK, LCK, SYK | ALOX15 500/4885TSHR 3351/4885CASP1 538/4885 |
| US-11974999-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | ALOX15 4237/4885TSHR 1864/4885CASP1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.